Application No.: 09/995,631

(activation) antigen), include at least six receptors which interact specifically with fibronectin; collagen and/or laminin as ligands. Within the VLA family, the integrin VLA-4 (α 4 β 1) is atypical in so far as it is mainly restricted to lymphoid and myeloid cells and is responsible in these for cell-cell interactions with a large number of other cells. For example, VLA-4 mediates the interaction of T and B lymphocytes with the heparin II-binding fragment of human plasma fibronectin (FN). The binding of VLA-4 with the heparin II-binding fragment of plasma fibronectin is especially based on an interaction with an (SEQ ID NO: 1) LDVP sequence. In contrast to the fibrinogen or vitronectin, VLA-4 is not a typical RGD-binding integrin (Kilger and Holzmann, J. Mol. Meth. 1995, 73, 347).

Page 88, at the end of the specification, please insert the printed Sequence Listing submitted concurrently herewith.

REMARKS

Applicants submit this Amendment to insert the required SEQ ID NO of the Sequence Listing filed concurrently herewith and to indicate the insertion point for the Sequence Listing.

Applicants respectfully request examination on the merits of this application.

Respectfully submitted,

March 8, 2002

Date

Patricia D. Granados Reg. No. 33,683

Heller Ehrman White & McAuliffe LLP

1666 K Street, N.W., Suite 300

Washington, DC 20006

Telephone: (202) 912-2000

Facsimile:

(202) 912-2020

PATENT TRADEMARK OFFICE